News

The Cooper Companies, Inc.’s COO first-quarter fiscal 2024 results are scheduled to be released on Feb 29, after the closing bell.

In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate. Its earnings beat estimates in two of the trailing four quarters and met twice, delivering an average surprise of 2.84%.

Q1 Estimates

The Zacks Consensus Estimate for revenues is pegged at $915.2 million for the soon-to-be-reported quarter, indicating a 6.6% increase from the year-ago quarter’s level. The same for earnings is pinned at 79 cents per share, implying an 8.2% improvement from the prior-year period’s reported number.

Factors to Note

Cooper Companies reports revenues under two major segments — CooperVision (CVI) and CooperSurgical (CSI). Both these segments displayed strength in the past few quarters. This trend is likely to have continued in the first quarter of fiscal 2024.

Solid performance across the company’s daily silicone hydrogel portfolio and myopia management, and strength in torics and multifocals are expected to have contributed to the CVI segment’s performance.

The segment’s revenues for fiscal 2024 are projected in the range of $2.548-$2.594 billion (organic growth of 7-9%). This momentum is likely to be reflected in the upcoming quarterly results.

CSI displayed strength in the fourth quarter of fiscal 2023, with revenues of $304.2 million. The top line increased 7% year over year on a constant currency basis and 6% on a reported basis.

The segment benefited from fertility as well as surgical products. This trend is likely to have continued in the quarter to be reported.

For fiscal 2024, CSI revenues are expected to be in the range of $1.261-$1.283 billion (4-6% organic growth). This strength is likely to be reflected in the upcoming quarterly results.

During the previous reported quarter, the company witnessed a significant increase in revenues with respect to MyDay daily silicone hydrogel lenses. The momentum is likely to have continued in the fiscal first quarter, courtesy of the excellent progress of its key accounts and entry into new pilot programs with retailers and buying groups globally.

Cooper Companies has been witnessing higher demand for contact lenses, driven by the recent global transition to daily contact lenses by customers. The company’s advancements in customized product offerings are expected to have contributed to its fiscal first-quarter performance.

The Cooper Companies, Inc. Price and EPS Surprise

What the Zacks Model Unveils

Our proven model does not conclusively predict an earnings beat for PDCO this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (78 cents per share) and the Zacks Consensus Estimate is -0.99%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: The company carries a Zacks Rank #3 at present.

Stocks to Consider

Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.

SiBone SIBN has an Earnings ESP of +1.75% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

SIBN has an estimated earnings growth rate of 36.3% for fiscal 2023. It delivered a trailing four-quarter average earnings surprise of 24.21%.

Merit Medical Systems MMSI has an Earnings ESP of +0.43% and a Zacks Rank of 3 at present.

The stock has an estimated earnings growth rate of 10% for fiscal 2023. MMSI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 14.41%.

Universal Health Services UHS has an Earnings ESP of +1.44% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 5.3% for 2023.

UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.47%.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Just Released: Zacks Top 10 Stocks for 2024

Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.